Skip to main
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways PLC is positioned favorably as it advances its proprietary psilocybin therapy, COMP360, especially as it prepares for phase III data release, with a potential increase in stock value contingent on positive results. The company's bolstered probability of success now stands at 75% due to improved regulatory familiarity and robust clinical study outcomes, which indicate significant patient improvements in treatment-resistant depression. Additionally, the development of an expanding global network of treatment centers and further indications under development enhances Compass Pathways's prospect of establishing leadership in the CNS therapeutics sector.

Bears say

Compass Pathways PLC faces significant financial risks, primarily stemming from the potential failure of its lead product, COMP360, to demonstrate clinically meaningful benefits in upcoming Phase III trials, which could severely impact investor sentiment and stock valuation. The company is also burdened by its non-revenue-generating status and substantial ongoing expenses related to research and development and general administrative activities, heightening overall stock price volatility. Additionally, mounting competition in the psychedelic space, coupled with challenges related to regulatory compliance and the commercialization of its products, presents a concerning outlook for the company’s long-term financial stability.

COMPASS Pathways (CMPS) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Buy based on their latest research and market trends.

According to 8 analysts, COMPASS Pathways (CMPS) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.